Loading…
KRM Ayurveda (KRMAYURVED)₹232.60+0.58%Pharmaceuticals
In the Jun 2026 quarter (standalone), KRM Ayurveda reported sales of ₹32.25 Cr, up 31.0% from Jun 2025, and net profit of ₹9.11 Cr, up 123.8% year on year. For the year to Mar 2026, sales were ₹102 Cr and net profit ₹20.05 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 24.62 | 32.13 | 32.25 |
| Expenses | 18.49 | 21.25 | 20.31 |
| Operating Profit | 6.22 | 10.99 | 12.01 |
| OPM % | 25.2% | 34.2% | 37.2% |
| Other Income | 0.14 | 0.18 | 0.53 |
| Interest | 0.70 | 0.64 | 0.07 |
| Depreciation | 0.26 | 0.32 | 0.27 |
| Profit before tax | 5.43 | 10.26 | 12.26 |
| Tax % | 25.3% | 23.7% | 25.7% |
| Net Profit | 4.07 | 7.83 | 9.11 |
| EPS (Rs) | 270.49 | 3.68 | 4.28 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 88.85 | 66.82 | 76.79 | 102 |
| Expenses | 78.10 | 60.08 | 57.05 | 71.05 |
| Operating Profit | 10.99 | 7.99 | 19.01 | 30.02 |
| OPM % | 13.1% | 11.0% | 25.1% | 30.1% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.99 |
| Interest | 1.01 | 2.01 | 2.01 | 3.01 |
| Depreciation | 1.01 | 1.01 | 1.01 | 1.01 |
| Profit before tax | 10.02 | 5.01 | 16.04 | 27.07 |
| Tax % | 25.0% | 28.0% | 26.0% | 25.0% |
| Net Profit | 8.02 | 3.01 | 12.04 | 20.05 |
| EPS (Rs) | 5,082.60 | 2,279.54 | 808.78 | 9.49 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 0.14 | 21.00 |
| Reserves | 7.99 | 11.99 | 23.97 | 92.98 |
| Borrowings | 20.06 | 23.08 | 31.08 | 0.00 |
| Other Liabilities | 11.04 | 8.99 | 12.04 | 8.04 |
| Total Liabilities | 39.08 | 44.05 | 67.08 | 122 |
| Fixed Assets | 23.05 | 23.04 | 27.04 | 26.05 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 37.90 |
| Other Assets | 16.03 | 21.01 | 40.04 | 58.07 |
| Inventories | 0.68 | 1.46 | 7.71 | 9.05 |
| Trade receivables | 7.73 | 5.52 | 12.09 | 22.66 |
| Cash & equivalents | 0.24 | 0.51 | 2.03 | 9.48 |
| Total Assets | 39.08 | 44.05 | 67.08 | 122 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 4.01 | −0.99 | 0.00 | 1.01 |
| Cash from investing activity | −22.94 | 0.00 | −3.99 | −29.89 |
| Cash from financing activity | 19.07 | 1.01 | 6.02 | 37.16 |
| Net cash flow | 0.00 | 0.00 | 2.01 | 7.02 |
| Capex | 23.10 | 0.55 | 4.74 | 0.93 |
| Free cash flow | −19.98 | −0.99 | −4.99 | 0.00 |
| CFO / OP % | 36.0% | 33.0% | 14.0% | 29.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 32 | 30 | 58 | 82 |
| Inventory days | 13 | 53 | 296 | 225 |
| Days payable | 100 | 141 | 205 | 80 |
| Cash conversion cycle | −54 | −57 | 150 | 228 |
| Working capital days | 8 | 47 | 63 | 279 |
| ROCE % | — | 22.0% | 42.0% | 35.0% |
For the Jun 2026 quarter, KRM Ayurveda reported sales of ₹32.25 Cr, up 31.0% year on year and net profit of ₹9.11 Cr, up 123.8% year on year. The operating margin was 37.2%.
KRM Ayurveda's sales for the year to Mar 2026 were ₹102 Cr.
Net profit for the year to Mar 2026 was ₹20.05 Cr. Earnings per share over the same trailing period were ₹9.49.
KRM Ayurveda reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹9.48 Cr.
Cash from operations was ₹1.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0 Cr.